Comprehensive diagnostic model of metastasis in prostate cancer: Individual and combined bioscore model of ADC value, Gleason score, and PSA

Abstract

Prostate cancer (PCa) metastasis significantly influences treatment decisions and prognosis. This study evaluated the individual and combined diagnostic ability of apparent diffusion coefficient (ADC), Gleason score and prostate-specific antigen (PSA) in detecting metastasis. The study included data from 120 biopsy-confirmed PCa patients treated from 2019 to 2023. Whole-body MRI images, incorporating high-resolution T2 and axial DWI sequences, were evaluated by experienced radiologists. Receiver operating characteristic (ROC) curves and logistic regression models were used to assess the diagnostic performance of ADC, Gleason score, and PSA in detecting metastasis. The prevalence of PCa metastasis was 25.0%, with pelvic lymph node metastasis (16.7%) and bony metastasis (12.5%) being most prevalent. Patients with PCa metastasis had significantly lower ADC values, higher Gleason scores, and higher PSA levels compared to those without metastasis. Individually, an ADC cut-off of ≤549.00 mm²/s was the best marker for detecting metastasis. The combined bioscore model including PSA, ADC values and Gleason score was the best independent predictor, correlating with a 159-fold increased likelihood of detecting PCa metastasis. This study demonstrated the prognostic ability of PCa markers in detecting metastasis. ADC was an independent, sensitive, specific, and accurate diagnostic marker. The combined bioscore model of ADC, PSA and Gleason score significantly enhanced the identification of patients with PCa metastasis.

Keywords

African men / diagnostics marker / metastasis / prostate cancer / tumor

References

[1] Basic Information About Prostate Cancer. CDC. Accessed February 22, 2024. https://www.cdc.gov/cancer/prostate/basic_info/index.htm

[2] Pereira-Azevedo N, Verbeek JFM, Nieboer D, Bangma CH, Roobol MJ. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome. Transl Androl Urol. 2018; 7(1): 18-26.

[3] Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level≤ 4.0 ng per milliliter. New Engl J Med. 2004; 350(22): 2239-2246.

[4] Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochimica et Biophysica Acta. 2014; 1846(1): 99-112.

[5] Stephan C, Cammann H, Meyer HA, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett. 2007; 249(1): 18-29.

[6] Catalona WJ, Partin AW, Sanda MG, et al. A multi-center study of [– 2] pro-prostate-specific antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA range. J Urol. 2011; 185(5): 1650-1655.

[7] Stamey TA, Caldwell M, McNEAL JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004; 172(4 Part 1): 1297-1301.

[8] Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003; 16(2): 95-101.

[9] Retter A, Gong F, Syer T, Singh S, Adeleke S, Punwani S. Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly. Mol Oncol. 2021; 15(10): 2565-2579.

[10] Manetta R, Palumbo P, Gianneramo C, et al. Correlation between ADC values and Gleason score in evaluation of prostate cancer: multicentre experience and review of the literature. Gland Surg. 2019; 8(Suppl 3): S216-S222.

[11] Onal C, Erbay G, Guler OC, Oymak E. The prognostic value of mean apparent diffusion coefficient measured with diffusion-weighted magnetic resonance image in patients with prostate cancer treated with definitive radiotherapy. Radiother Oncol. 2022; 173: 285-291.

[12] Team RDC. R: A language and environment for statistical computing. 2010.

[13] Hoffmann MA, Taymoorian K, Ruf C, et al. Diagnostic performance of multiparametric magnetic resonance imaging and fusion targeted biopsy to detect significant prostate cancer. Anticancer Res. 2017; 37(12): 6871-6877.

[14] Wang L, Yu F, Yang L, et al. 68Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: perspective of radiologist. Medicine. 2020; 99(36): e20755.

[15] Onal C, Erbay G, Oymak E, Guler OC. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients. Radiother Oncol. 2023; 184: 109677.

[16] Anwar SS, Anwar Khan Z, Shoaib Hamid R, et al. Assessment of apparent diffusion coefficient values as predictor of aggressiveness in peripheral zone prostate cancer: comparison with Gleason score. Int Sch Res Notices. 2014; 2014: 1-7.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.